May 4, 2020 / 5:08 AM / 25 days ago

BRIEF-Newron Pharmaceuticals To Prioritize Its Phase III Development Program Of Evenamide In Schizophrenia

May 4 (Reuters) - NEWRON PHARMACEUTICALS SPA:

* REPORTS TOP-LINE RESULTS FROM ITS STARS STUDY EVALUATING SARIZOTAN IN PATIENTS WITH RETT SYNDROME

* PIVOTAL TRIAL DID NOT MEET PRIMARY OR SECONDARY EFFICACY VARIABLES

* NEWRON WILL PRIORITIZE ITS PHASE III DEVELOPMENT PROGRAM OF EVENAMIDE IN SCHIZOPHRENIA AND EVALUATE ADDITIONAL PIPELINE CANDIDATES Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below